뒤로
Passage Bio Inc(PASG) 가격
PASG 주가 차트
PASG 수입
Passage Bio Inc
$12.87
-9.87%
$-1.41
종가: Jan 16, 16:00:00 GMT-5
$12.87
0%
$0
애프터마켓: Jan 16, 20:00:00 GMT-5
주요 통계
이전 종가
$14.28
시가
$14.32
일일 범위
$12.5 - $14.8
52주 범위
$5.12 - $20
거래량
40.3K
평균 거래량
58.4K
EPS(TTM)
-14.47
배당수익률
--
시가총액
$40.9M
PASG란 무엇인가요?
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.